Product Program year 2024 Source: CMS Open Payments

Latuda

Drug Cns

NDC 63402-304-30

Open in the dashboard

General payments

$7,770,991

204,565 payments

Research payments

$0

0 payments

Through program year 2024, $7,770,991 in general payments and $0 in research payments were reported against Latuda (Cns).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2024 General $18,129 22
2023 General $34,636 269
2022 General $816,167 49,848
2021 General $1,161,620 63,801
2020 General $1,732,071 28,160
2019 General $4,008,368 62,465

Breakdown

Who paid General payments · program years 2019–2024
  1. Sunovion Pharmaceuticals Inc. $7,548,926 204,131 payments
  2. Sumitomo Dainippon Pharma Co., Ltd. $218,223 198 payments
  3. Sumitomo Pharma America, Inc. $3,842 236 payments
Top recipients General payments · program year 2024
  1. John Kane Psychiatry · Glen Oaks, NY $6,984 39% · 10 payments
  2. Takuya Saito Child & Adolescent Psychiatry · Suginami $6,622 37% · 10 payments
  3. Christoph Correll Psychiatry · Glen Oaks, NY $4,523 25% · 2 payments

Each share is of general payments naming this product in 2024.

Specialties paid General payments · program year 2024
  1. Psychiatry Psychiatry & Neurology $11,507 63% · 2 practitioners
  2. Child & Adolescent Psychiatry Psychiatry & Neurology $6,622 37% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. New York $11,507 100% · 2 recipients

Each share is of general payments naming this product in 2024 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

11,984

Prescriptions dispensed, refills included

Drug cost

$18,040,288

Paid at the pharmacy, in all

Prescribers

625

With 11 or more claims of it

Medicare Part D drugs matched to LATUDA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Latuda Lurasidone Hcl Same name 625 11,984 $18,040,288

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Alexander Pinkusovich Psychiatry NY 736 $1,030,358 None on record
Inna Markhasina Psychiatry NY 447 $596,955 None on record
Isak Isakov Psychiatry NY 167 $222,311 None on record
Inessa Meyerovich Psychiatry NY 119 $156,017 None on record
Laura Amram Psychiatry NY 100 $130,574 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
204,565 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record